Increased incidence of necrotizing enterocolitis in premature infants born to HIV-positive mothers

AIDS

Volumn 19, Issue 14, 2005, Pages 1487-1493

  Desfrere, Luc ^a   De Oliveira, Isabelle ^a   Goffinet, François ^b   El Ayoubi, Mayass ^a   Firtion, Ghislaine ^a   Bavoux, Françoise ^b   Jarreau, Pierre Henri ^a   Moriette, Guy ^a  

^a Université Paris V René Descartes ^*  (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Antiretroviral agents; Gastrointestinal disease; HIV; Necrotizing enterocolitis; Newborn; Premature

Indexed keywords

ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; ZIDOVUDINE;

ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FETUS HEART RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MATERNAL DISEASE; MULTIVARIATE ANALYSIS; NECROTIZING ENTEROCOLITIS; NEWBORN; NEWBORN CARE; POLYMERASE CHAIN REACTION; PREGNANCY; PREMATURITY; PRENATAL GROWTH; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMATIC REVIEW; X RAY;

EID: 25844475148     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000183123.09206.07     Document Type: Article

References (30)

1. Caplan MS, Jilling T. New concepts in necrotizing enterocolitis. Curr Opin Pediatr 2001; 13:111-115.
2. Mannick E, Udall JN Jr. Neonatal gastrointestinal mucosal immunity. Clin Perinatol 1996; 23:287-304.
3. Neuman MI, Molle Z, Handelsman EL, Desai N, Orentlicher RJ, Rabinowitz SS. Neonatal hypoperistalsis associated with perinatal zidovudine administration. J Perinatol 1998; 18:20-23.
4. Nielsen SD, Jeppesen DL, Kolte L, Clark DR, Sorensen TU, Dreves A-M, et al. Impaired progenitor cell function in HIV-negative infants of HIV-positive mothers results in decreased thymic output and low CD4 counts. Blood 2001; 98:398-404.
5. Clerici M, Saresella M, Colombo F, Fossati S, Sala N, Bricalli D, et al. T-lymphocyte maturation abnormalities in uninfected newborns and children with vertical exposure to HIV. Blood 2000; 96:3866-3871.
6. Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am 1986; 33:179-201.
7. Lubchenco LO, Hansman C, Dressler M, Boyd E. Intrauterine growth as estimated from live-born birth-weight data at 24 to 42 weeks of gestation. Pediatrics 1963; 32:793-800.
8. Bhatt AB, Tank PD, Barmade KB, Damania KR. Abnormal Doppler flow velocimetry in the growth restricted foetus as a predictor for necrotizing neterocolitis. J Postgrad Med 2002; 48:182-185.
9. The International Neonatal Network. The CRIB (clinical risk index for babies) score: a tool for assessing initial neonatal risk and comparing performance of neonatal intensive care units. Lancet 1993; 342:193-198.
10. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173-1180.
11. Mirochnick M, Capparelli EV, Dankner WM, Sperling RS, van Dyke R, Spector SA. Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus. Antimicrob Agents Chemother 1998; 42:808-812.
12. Capparelli EV, Mirochnick M, Dankner WM, Blanchard S, Mofenson L, McSherry GD, et al. Pharmacokinetics and tolerance of zidovudine in preterm infants. J Pediatr 2003; 142:47-52.
13. Guthrie SO, Gordon PV, Thomas V, Thorp JA, Peabody J, Clark RH. Necrotizing enterocolitis among neonates in the United States. J Perinatol 2003; 23:278-285.
14. Nielsen HV, Harvey-Wilkes K, MacKinnon B, Hung S. Neonatal outcome of very premature infants from multiple and singleton gestations. Am J Obstet Gynecol 1997; 177:653-659.
15. Bauer CR, Morrison JC, Poole WK, Korones SB, Boehm JJ, Rigatto H, et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. Pediatrics 1984; 73:682-688.
16. Kamitsuka MD, Horton MK, Williams MA. The incidence of necrotizing enterocolitis after introducing standardized feeding schedules for infants between 1250 and 2500 grams and less than 35 weeks of gestation. Pediatrics 2000; 105:379-384.
17. Chougnet C, Kovacs A, Baker R, Mueller UN, Luban LCD, Liewehr J, et al. Influence of human immunodeficiency virus-infected maternal environment on development of infant interleukin-12 production. J Infect Dis 2000; 181:1590-1597.
18. Zisman DA, Kunkel SL, Strieter RM, Gauldie J, Tsai WC, Bramson J, et al. Anti-interleukin-12 therapy protects mice in lethal endotoxemia but impairs bacterial clearance in murine Escherichia coli peritoneal sepsis. Shock 1997; 8:349-356.
19. Nadler EP, Dickinson E, Knisely A, Zhang XR, Boyle P, Beer-Stolz D, et al. Expression of inducible nitric oxide synthase and interleukin-12 in experimental necrotizing enterocolitis. J Surg Res 2000; 92:71-77.
20. Nadler EP, Stanford A, Zhang XR, Schall LC, Alber SM, Watkins SC, et al. Intestinal cytokine gene expression in infants with acute necrotizing enterocolitis: interleukin-11 mRNA expression inversely correlates with extent of disease. J Pediatr Surg 2001; 36:1122-1129.
21. Sperling RS, Shapiro DE, McSherry GD, Britto P, Cunningham BE, Culnane M, et al. Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study. AIDS 1998; 12:1805-1813.
22. Book LS, Herbst JJ, Atherton SO, Jung AL. Necrotizing enterocolitis in low-birth-weight infants fed an elemental formula. J Pediatr 1975; 87:602-605.
23. Masini A, Scotti C, Calligaro A, Cazzalini O, Stivala LA, Bianchi L, et al. Zidovudine-induced experimental myopathy: dual mechanism of mitochondrial damage. J Neurol Sci 1999; 166:131-140.
24. Haas RH. A comparison of genetic mitochondrial disease and nucleoside analogue toxicity. Does fetal nucleoside toxicity underlie reports of mitochondrial disease in infants born to women treated for HIV infection? Ann N Y Acad Sci 2000; 918:247-261.
25. Gerschenson M, Poirier MC. Fetal patas monkeys sustain mitochondrial toxicity as a result of in utero zidovudine exposure. Ann N Y Acad Sci 2000; 918:269-281.
26. Gerschenson M, Erhart SW, Paik CY, St Claire MC, Nagashima K, Skopets B, et al. Fetal mitochondrial heart and skeletal muscle damage in Erythrocebus patas monkeys exposed in utero to 3′-azido-3′-deoxythymidine. AIDS Res Hum Retroviruses 2000; 16:635-644.
27. Poirier MC, Divi RL, Al-Harthi L, Olivero OA, Nguyen V, Walker B, et al. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr 2003; 33:175-183.
28. Barret B, Tardieu M, Rustin P, Lacroix C, Chabrol B, Desguerre I, et al. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS 2003; 17:1769-1785.
29. Alimenti A, Burdge DR, Ogilvie GS, Money DM, Forbes JC. Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy. Pediatr Infect Dis J 2003; 22:782-789.
30. Chinnery PF, Jones S, Sviland L, Andrews RM, Parsons TJ, Turnbull DM, et al. Mitochondrial enteropathy: the primary pathology may not be within the gastrointestinal tract. Gut 2001; 48:121-124.